Workflow
康弘药业股价跌5.03%,中信建投基金旗下1只基金重仓,持有40万股浮亏损失79.2万元
Xin Lang Cai Jing·2025-09-19 05:44

Core Viewpoint - Kanghong Pharmaceutical experienced a 5.03% decline in stock price, closing at 37.42 CNY per share, with a total market capitalization of 34.476 billion CNY [1] Company Overview - Chengdu Kanghong Pharmaceutical Group Co., Ltd. was established on October 3, 1996, and went public on June 26, 2015. The company is located in Jin Niu District, Chengdu, Sichuan Province [1] - The main business activities include research, production, and sales of chemical drugs, traditional Chinese medicine, and biological products [1] Revenue Composition - The revenue composition of Kanghong Pharmaceutical is as follows: - Biological drugs: 54.83% - Traditional Chinese medicine: 32.49% - Chemical drugs: 12.50% - Others: 0.15% - Additional: 0.03% [1] Fund Holdings - CITIC Jiantou Fund has a significant holding in Kanghong Pharmaceutical, with its CITIC Jiantou Medical Health A fund (010090) holding 400,000 shares, representing 3.85% of the fund's net value [2] - The fund has reported a floating loss of approximately 792,000 CNY as of the latest update [2] Fund Performance - CITIC Jiantou Medical Health A fund was established on September 24, 2020, with a current size of 185 million CNY. Year-to-date returns are 45.86%, ranking 1208 out of 8172 in its category [2] - Over the past year, the fund has achieved a return of 52.35%, ranking 2999 out of 7980 [2] - Since inception, the fund has experienced a loss of 14.44% [2] Fund Manager Information - The fund manager of CITIC Jiantou Medical Health A is Xie Wei, who has been in the position for 7 years and 109 days. The total asset size under management is 1.987 billion CNY [2] - The best fund return during Xie Wei's tenure is 111.59%, while the worst return is -17.87% [2]